Age-Related Macular Degeneration Clinical Trial
Official title:
A Study to Evaluate the Sensitivity and Specificity of a Device to Measure Dark Adaptation in Subjects With and Without Early Macular Disease
Age Related Macular Disease (AMD) is easily the leading cause of blindness in older people
in developed countries. It affects between 30 and 50 million individuals worldwide, with
around 30% of the over 65's showing early signs of the disease. Severe AMD has a devastating
impact on the quality of life; it causes extensive visual impairment, making reading
difficult and driving impossible. Patients lose their independence and become a major burden
on public health systems.
Present treatment options are limited. Many new therapies are under development and all will
need evaluation using a test with high specificity and sensitivity for early AMD. The
present application will develop such an instrument. The prototype was funded by a previous
i4i FS (feasibility study ll-FS-0110-14036). The new device measures sensitivity to a dim
flickering light using the same principle as an established european conformity marked (CE
marked) instrument. The original method involved lights of different wavelengths and higher
intensities.
The instrument in this study assesses night vision, which is selectively damaged in early
stage AMD. In low lighting, the investigators vision depends on specialized rod
photoreceptors. Cone photoreceptors, which provide daytime vision, remain normal in the
early stages of the disease. By the time patients complain of reduced (cone-based) visual
acuity, they will have had the disease for many years and lost many thousands of
photoreceptors.
In a clinical environment dark adaptation (DA) is measured by exposing the patient to a
brief bright light and then measuring their sensitivity to a flickering light. This
sensitivity recovery has a typical appearance; an early rapid recovery mediated by the
colour vision system (cone photoreceptors) and a slower recovery of the low light system
(rod photoreceptors).
If the measurements are made against a black background then a bi exponential model is
suitable, however if a dim luminous background is used then the recovery is better modelled
by a exponential bi linear model. We will use the exponential bilinear model, which has
seven parameters. The parameters are as follows; the exponential cone phase is modelled by
the cone threshold, cone coefficient, and cone time constant. The S2 rod phase is modelled
by its commencement time. This is the time when the rod system becomes more sensitive than
the cone system, sometimes called the cone-rod break point (alpha) and the slope of the
subsequent thresholds. The late rod phase (S3) is similarly modelled by a transition time or
rod-rod breakpoint (beta) and its slope.
If the initial bright light is sufficiently intense then the recovery of the rod phase (S2)
is termed rate limited. There is evidence that this recovery rate is a useful measure of the
health of the light sensing layer of the eye an adjoining tissues, the retina, retinal
pigment epithelium and choroid. It is these tissues that are thought to be affected in age
related macular disease.
In this study we will measure rate of rod recovery sometimes called the S2 phase. We want to
see whether this measurement can be used to identify patients with and without early macular
disease.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |